Human Insulin

Global Human Insulin Market to Reach US$79.1 Billion by 2030

The global market for Human Insulin estimated at US$50.1 Billion in the year 2023, is expected to reach US$79.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. HI Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$70.6 Billion by the end of the analysis period. Growth in the HI Delivery Devices segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.2 Billion While China is Forecast to Grow at 10.2% CAGR

The Human Insulin market in the U.S. is estimated at US$13.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$18.9 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Human Insulin Market - Key Trends and Drivers Summarized

Why Is Human Insulin Pivotal in Diabetes Management?

Human insulin is a vital component in the management of diabetes, a chronic condition that affects millions worldwide. Insulin, a hormone produced by the pancreas, regulates blood sugar levels, and people with diabetes often need external insulin to manage their condition. Human insulin is synthetically produced using recombinant DNA technology and is available in various forms, including short-acting, long-acting, and intermediate-acting insulin. These formulations allow for more precise blood sugar control, reducing the risk of complications such as hypoglycemia or hyperglycemia. Human insulin has revolutionized diabetes care, enabling patients to manage their condition more effectively and lead healthier lives.

How Are Technological Advancements Shaping the Human Insulin Market?

Technological advancements in insulin delivery systems, such as insulin pens, pumps, and continuous glucose monitors (CGMs), have significantly enhanced the human insulin market. Insulin pumps, for instance, provide continuous insulin infusion, mimicking the natural release of insulin by the pancreas, while insulin pens offer greater convenience and dosing accuracy. The integration of CGMs with insulin pumps has allowed for more precise and real-time adjustments to insulin dosages, improving glycemic control for patients. Furthermore, advancements in biosimilar human insulin, which are biologically similar to existing insulin products, are driving down costs and increasing accessibility for patients in need of affordable diabetes management solutions.

How Do Market Segments Define the Growth of the Human Insulin Market?

Product types include regular human insulin and insulin analogs, with insulin analogs dominating the market due to their improved pharmacokinetic properties. Delivery methods include syringes, insulin pens, and insulin pumps, with insulin pens leading the market because of their ease of use and convenience. Applications of human insulin span across type 1 and type 2 diabetes, with type 2 diabetes representing the largest segment due to the high global prevalence of the disease. The market also serves various end-users, including hospitals, clinics, and homecare settings, with homecare seeing rapid growth as patients seek greater independence in managing their condition.

What Factors Are Driving the Growth in the Human Insulin Market?

The growth in the human insulin market is driven by several factors, including the rising prevalence of diabetes, advancements in insulin delivery technologies, and increasing access to affordable biosimilar insulin. The global rise in obesity, sedentary lifestyles, and aging populations has contributed to a sharp increase in diabetes cases, fueling the demand for effective insulin therapies. Technological innovations in insulin pumps and continuous glucose monitoring systems have improved patient outcomes, making diabetes management more efficient and less burdensome. Additionally, the introduction of biosimilar human insulin products has increased market competition, lowering costs and improving accessibility for patients, particularly in developing regions. Ongoing research into next-generation insulin formulations and delivery systems is expected to further propel market growth in the coming years.

 

Select Competitors (Total 43 Featured) -

• Becton, Dickinson and Company
• Biocon Limited
• Biodel, Inc.
• Boehringer Ingelheim International GmbH
• Boston Scientific Corp.
• Braun Melsungen AG
• ELI Lilly and Company
• Julphar (Also Known as Gulf Pharmaceutical Industries)
• Medtronic Plc
• Merck & Co., Inc.
• NOVO Nordisk A/S
• Sanofi
• Tonghua Dongbao Pharmaceutical
• Wockhardt Limited
• Ypsomed AG

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.